Document Type : Research Paper
Authors
1 Department of Chemistry , College of Education for Women ,University of Anbar
2 DEPARTMENT OF CHEMISTRY , COLLEGE OF EDUCATION FOR WOMEN ,UNIVERSITY OF ANBAR
10.37652/juaps.2017.175957
Abstract
The aim of this study is to design and prepare set of compounds can work as patent inhibitors of xanthine oxidase .The designing of inhibitors was carried out via MOE software and then after choosing the best theoretical inhibitor we prepared, dentified and characterize them by FT-IR, 1HNMR and13CNMR spectroscopy, and C.H.N elements data and the effectiveness of the prepared compounds to inhibit the enzyme XO in vitro.
Main Subjects
1. Meneshian A, Bulkley GB et al. The physiology of endothelial xanthine oxidase: from urate catabolism to reperfusion injury to inflammatory signal transduction. Microcirculation (2002): 9: 161-75.
2. Harrison R. Structure and function of xanthine oxidoreductase: Where are we now?Free Rad Biol Med. 2002;33:774-797.
3. Zhong-Lu You, Da-Hua Shi, Chen Xu, et al. Schiff base transition metal complexes as novel inhibitors of xanthine oxidase. Eur. J. Med. Chem. 2008;43:862-871.
4 . Doehner W, Anker SD et al . Xanthine oxidase inhibition for chronic heart failure:is allopurinol the next therapeutic advance in heart failure. Heart. 2005;91:707-709.
5. Berry CE, Hare JM et al. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications .J Physiol. 2004;555:589-606.
6 . Lee C, Liu Xk, Zweier JL., et al. Regulation of xanthine oxidase by nitric oxide and Peroxynitrite. J Biol Chem. 2000;275:9369-937.
7 . Fernandes AS, Gaspar J, Cabral MF,et al. Macrocyclic copper (II) Complexes: superoxide scavenging activity, Structural studies and cytotoxicity evaluation. J Inorg Biochem. 2007;101:849-858.
8. Congreve M, Marshall F et al. The impact of GPCR structures on pharmacology and structure-based drug design. Br. J. Pharmacol. 2010; 159:986–996.
9. Vilar S, Cozza G, Moro S., et al. Medicinal Chemistry and the Molecular Operating Environment (MOE): Application of QSAR and Molecular Docking to Drug Discovery. Curr. Top. Med. Chem. 2008;8:1555.
10. Dhiman R. , Sharma S.,et al . Design and synthesis of aza – flavones as new class of xanthine oxidase inhibitors . Arch . Pharma. Chem. Life Sci.2013,346,7-16.
11. Vogel, H.G Drug Discovery and Evaluation, Pharmacological Assay,2003; 2nd edition, Springer-Verlag, 1043.
12. M. U Maheshwari, K. Kumar, Xanthine oxidase inhibitory activity of some Indian medical plants. Journal of Ethnopharmacology. 2007; 109:547.
13. Kong, L.D., Y. Cai, et al. Inhibition of xanthine oxidase by some Chinese medicinal plants used to treat gout. J. Ethnopharmacol. 73: 199–207, 2000.
14. Nagamatsu T., Yamasaki H., et al. Novel xanthine oxidase inhibitor studies. Part 2. Synthesis and xanthine oxidase inhibitory activities of 2-substituted 6-alkylidenehydrazino- or 6-arylmethylidenehydrazino-7H-purines and 3- and/or 5-substituted 9H-1,2,4-triazolo[3,4-i ] purines. Journal of Chemical Society,1999; 1: 3117.
15. Umamaheswari M. , Madeswaran A., et al .In Silico Docking Studies and In Vitro Xanthine Oxidase Inhibitory Activity of Commercially Available Flavonoids and Polyphenolic Compounds.Journal of Pharmacy Research 2011,4(10),3460-3462.
16. Amat N. , Umar A., et al. Traditional Uighur Medicine Karapxa decoction,inhibits liver xanthine oxidase and reduces serum uric acid concentrations in hyperuricemic miceand scavenges free radicals in vitro. Amat et al. BMC Complementary and Alternative Medicine (2015) 15:131.
17. El-Bassossy H. M., and Watson M. L. Xanthine oxidase inhibition alleviates the cardiac complications of insulin resistance: effect on low grade inflammation and the angiotensin system. El-Bassossy and Watson Journal of Translational Medicine (2015) 13:82.
18. Sagor Md., Tabassum N., et al . Xanthine Oxidase Inhibitor, Allopurinol, Prevented Oxidative Stress, Fibrosis, and Myocardial Damage in Isoproterenol Induced Aged Rats. Hindawi Publishing Corporation Oxidative Medicine and Cellular Longevity
Volume 2015, Article ID 478039, 9 pages.
19. Kim Bo S., Serebreni L., et al . Cyclin-Dependent Kinase Five Mediates Activation of Lung Xanthine Oxidoreductase
in Response to Hypoxia. PLoS ONE 10(4) , 2015, 1-18 .
20 . Giordano C., Karasik O., et al. Uric Acid as a Marker of Kidney Disease: Review of the Current Literature. Hindawi Publishing Corporation Disease Markers Volume 2015, Article ID 382918, 6 pages.
21. Susic D. and Frohlich E. D. . Hyperuricemia: A Biomarker of Renal Hemodynamic Impairment. Cardiorenal Med 2015;5:175–182.
22. Ives A., Nomura J., et al. Xanthine oxidoreductase regulates macrophageIL1ß secretion upon NLRP3 inflammasome
Activation. NATURE COMMUNICATIONS , 2015, 6:6555, 1-11.
23. Cecerska-HeryT., Jesionowska A., et al. Xanthine Oxidoreductase Reference Values in Platelet-Poor Plasma and Platelets in Healthy Volunteers. Hindawi Publishing CorporationOxidative Medicine and Cellular LongevityVolume 2015, Article ID 341926, 6 pages.
24. Weidert E.R., Schoenborn S.O., et al. Inhibition of xanthine oxidase by the aldehyde oxidase inhibitor raloxifene: Implications for identifying molybdopterin nitrite reductases. Nitric Oxide. 2014 February 15; 37: 41–45.
25. Nanduri J., Vaddi D. R.,et al. (2015) HIF-1α Activation by Intermittent Hypoxia Requires NADPH Oxidase Stimulation by Xanthine Oxidase. PLoSONE 10(3) , 12 pages.
26. Yamaguchi M, Okamoto K., et al . (2015) The Effects of Xanthine Oxidoreductase Inhibitors on Oxidative Stress Markers following Global Brain Ischemia Reperfusion Injury in C57BL/6 Mice. PLoS ONE 10(7), 14 pages.
27. Rajan T. , and Muthukrishnan S.. Molecular docking studies of xanthine oxidase inhibitors identified from PSEUDARTHRIA VISCIDA. Thinagaran Rajan and Suriyavathana Muthukrishnan. / European Journal of Molecular Biology and Biochemistry. 2014;1(1):1-6.
28. Azam F., Prasad M.V.V. , et al . Molecular docking studies of 1-(substituted phenyl)-3-(naphtha [1, 2-d] thiazol-2-yl) urea/thiourea derivatives with human adenosine A2A receptor. Bioinformation. 2011, 6, 330.
29. Krovat E. M., Steindl T., et al. Recent Advances in Docking and Scoring . Current Computer-Aided Drug Design, 2005, 1, 93-102.
30. Boström J , Greenwood J.R., et al . Assessing the performance of OMEGA with respect to retrieving bioactive conformations. J Mol Graph Model. 2003;21:449.
31. Cos P., Ying L.,et al. Structure-activity relationship and classification of flavonoids as inhibitors of xanthine oxidase and super oxide scavengers. J Nat Prod, 61 (1998), pp. 71–76.
32. da Silva S.L., da Silva A.,et al. The influence of electronic, steric and hydrophobic properties of flavonoid compounds in the inhibition of the xanthine oxidase. Journal of Molecular Structure (Theochem) 684 (2004) 1–7.
33. Lin C.M., Chen C.S., et al. Molecular modeling of flavonoids that inhibits xanthine oxidase. Biochem. Biophys. Res. Commun. 2002;294:167- 172.
)
